Related Experiment Videos
A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses
Kamran Ghoreschi1, Ulrich Mrowietz, Martin Röcken
1Department of Dermatology, University of Tübingen, Liebermeisterstrasse 25, 72076 Tübingen, Germany.
Journal of Molecular Medicine (Berlin, Germany)
|July 25, 2003
Summary
Psoriasis treatments may work by shifting immune responses from harmful Th1 to beneficial Th2. Interleukin-4 (IL-4) therapy shows promise in managing this autoimmune skin condition.
Area of Science:
- Immunology
- Dermatology
- Autoimmune Diseases
Background:
- Psoriasis is an autoimmune disorder driven by Th1 lymphocytes, characterized by skin inflammation, keratinocyte hyperproliferation, and immune cell infiltration.
- The pathogenesis involves activation of CD4+ T lymphocytes, with interleukin-12 (IL-12) promoting Th1 polarization and interferon-gamma (IFN-γ) production.
- STAT and T-bet activation are crucial for Th1 development, leading to pathological skin reactions in psoriasis.
Purpose of the Study:
- To review the potential of various systemic therapies to induce Interleukin-4 (IL-4) and promote Th2 immune responses in psoriasis.
- To explore the underestimated role of Th2 induction as a therapeutic mechanism in Th1-mediated autoimmune diseases like psoriasis.
- To highlight IL-4 as a key cytokine in shifting immune balance towards an anti-inflammatory phenotype.
Main Methods:
- Literature review of conventional and newer systemic therapies for psoriasis.
- Analysis of studies examining the immunomodulatory effects of these therapies, focusing on cytokine induction.
- Evaluation of evidence for Th2 phenotype induction in skin-infiltrating lymphocytes.
Main Results:
- Many systemic psoriasis therapies, previously considered primarily immunosuppressive, demonstrate the ability to induce IL-4 production.
- Therapeutic improvement in psoriasis is associated with the induction of a Th2 phenotype in skin-infiltrating lymphocytes.
- IL-4, a potent Th2-inducing cytokine, has shown safety and efficacy in treating psoriasis.
Conclusions:
- Th2 induction, particularly via IL-4, represents an underestimated therapeutic mechanism for Th1-mediated autoimmune diseases.
- Systemic therapies for psoriasis may exert beneficial effects by promoting immune deviation towards an anti-inflammatory Th2 response.
- Further research is warranted to elucidate the central role of IL-4 in controlling Th1-driven autoimmune conditions like psoriasis.